Insulet Aandeel

Insulet EPS

De Winst per Aandeel (EPS) van Insulet (PODD) per 23 aug 2026 bedraagt 3,50 USD. In het voorgaande jaar bedroeg Winst per Aandeel (EPS) 5,65 USD — een verandering van -38,08% (lager).

EPS

3,50USD

YoY

-38,08%

Laatst bijgewerkt:

Winst per Aandeel (EPS) van Insulet is 2026 3,50 USD. Winst per Aandeel (EPS) van Insulet was 2025 5,65 USD. Het is daarmee -38,08% lager lager dan het jaar ervoor.

De Insulet EPS historie

  • 3 jaar

  • 10 jaar

  • 25 jaar

  • Max

EPS
Date
EPS
1 jan 2023
2,95 USD
1 jan 2024
5,65 USD
1 jan 2025
3,50 USD
1 jan 2026 (e)
6,50 USD
1 jan 2027 (e)
7,72 USD
1 jan 2028 (e)
9,28 USD
1 jan 2029 (e)
11,14 USD
1 jan 2030 (e)
12,64 USD
De Insulet EPS historie
JAAREPSYoY
est12,64USD+13,43%
est11,14USD+20,02%
est9,28USD+20,34%
est7,72USD+18,65%
est6,50USD+85,97%
3,50USD-38,08%
5,65USD+91,22%
2,95USD+4.395,05%
0,07USD-72,70%
0,24USD+133,37%
0,10USD-43,21%
0,18USD+236,87%
0,05USD-111,70%
-0,46USD-8,37%
-0,50USD-61,06%
-1,29USD+40,83%
-0,92USD+11,47%
-0,82USD-23,53%
-1,08USD-10,77%
-1,21USD-10,15%
-1,34USD-36,09%
-2,10USD-37,09%
-3,34USD+70,76%
-1,95USD-95,01%
-39,19USD
Access this data via the Eulerpool API

Insulet Aandelenanalyse

Wat doet Insulet? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Insulet

Winst per Aandeel (EPS) van Insulet bedraagt 3,50 USD in 2026.

Winst per Aandeel (EPS) van Insulet is veranderd van 5,65 USD naar 3,50 USD, wat een verandering van -38,08% vertegenwoordigt. De waarde is lager dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Winst per Aandeel (EPS) Insulet sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

De winst per aandeel meet het deel van de bedrijfswinst dat aan elk uitstaand aandeel is toegewezen. Het is een sleutelmaatstaf voor het beoordelen van de winstgevendheid op aandeelbasis.

WPA = Nettowinst / Uitstaande aandelen

Access this data via the Eulerpool API

Winst-en-verliesrekening — Insulet

Alle kengetallen — Insulet